Compare Stocks: COYA, KMDA, TECX, and EDIT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
COYA Coya Therapeutics	$4.95 -0.8%	$4.78	$3.71 ▼ $7.75	$116.12M	0.58	154,529 shs	151,817 shs
EDIT Editas Medicine	$2.90 +2.1%	$2.86	$1.66 ▼ $4.33	$445.38M	2	3.40 million shs	3.09 million shs
KMDA Kamada	$8.08 +3.9%	$8.10	$6.55 ▼ $9.35	$464.64M	0.89	119,583 shs	72,765 shs
TECX Tectonic Therapeutic	$23.33 +2.5%	$29.58	$15.45 ▼ $39.53	$456.08M	3.28	259,078 shs	110,711 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
COYA Coya Therapeutics	-0.80%	+2.91%	+7.38%	-5.89%	-21.62%
EDIT Editas Medicine	+2.11%	+10.69%	+4.69%	-11.04%	-30.12%
KMDA Kamada	+3.86%	-2.77%	-1.58%	+13.48%	+18.13%
TECX Tectonic Therapeutic	+2.55%	+3.50%	-23.46%	-32.12%	+51.89%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
COYA Coya Therapeutics	$4.95 -0.8%	$4.78	$3.71 ▼ $7.75	$116.12M	0.58	154,529 shs	151,817 shs
EDIT Editas Medicine	$2.90 +2.1%	$2.86	$1.66 ▼ $4.33	$445.38M	2	3.40 million shs	3.09 million shs
KMDA Kamada	$8.08 +3.9%	$8.10	$6.55 ▼ $9.35	$464.64M	0.89	119,583 shs	72,765 shs
TECX Tectonic Therapeutic	$23.33 +2.5%	$29.58	$15.45 ▼ $39.53	$456.08M	3.28	259,078 shs	110,711 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
COYA Coya Therapeutics	-0.80%	+2.91%	+7.38%	-5.89%	-21.62%
EDIT Editas Medicine	+2.11%	+10.69%	+4.69%	-11.04%	-30.12%
KMDA Kamada	+3.86%	-2.77%	-1.58%	+13.48%	+18.13%
TECX Tectonic Therapeutic	+2.55%	+3.50%	-23.46%	-32.12%	+51.89%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
COYA Coya Therapeutics	2.71	Moderate Buy	$15.33	209.76% Upside
EDIT Editas Medicine	2.71	Moderate Buy	$5.83	101.15% Upside
KMDA Kamada	3.00	Buy	$13.50	67.08% Upside
TECX Tectonic Therapeutic	2.89	Moderate Buy	$77.80	233.48% Upside

Current Analyst Ratings Breakdown

Latest COYA, KMDA, TECX, and EDIT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/9/2026	KMDA Kamada	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Buy (B-) ➝ Buy (B)
10/8/2026	EDIT Editas Medicine	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Equal Weight ➝ Overweight	$4.00 ➝ $6.00
9/30/2026	TECX Tectonic Therapeutic	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$80.00
9/30/2026	TECX Tectonic Therapeutic	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/25/2026	COYA Coya Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/23/2026	EDIT Editas Medicine	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$5.00
9/22/2026	KMDA Kamada	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy (B-)
9/18/2026	KMDA Kamada	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$15.00
9/15/2026	COYA Coya Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$16.00
9/1/2026	TECX Tectonic Therapeutic	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
8/24/2026	COYA Coya Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy

(Data available from 10/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
COYA Coya Therapeutics	$7.95M	14.61	N/A	N/A	$2.06 per share	2.40
EDIT Editas Medicine	$40.52M	10.99	N/A	N/A	$0.28 per share	10.36
KMDA Kamada	$180.46M	2.57	$0.61 per share	13.23	$4.68 per share	1.73
TECX Tectonic Therapeutic	N/A	N/A	N/A	N/A	$13.43 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
COYA Coya Therapeutics	-$21.23M	-$1.07	N/A	N/A	N/A	-270.22%	-52.05%	-46.34%	11/11/2026 (Estimated)
EDIT Editas Medicine	-$160.06M	-$0.75	N/A	N/A	N/A	-157.32%	-196.63%	-38.17%	11/9/2026 (Estimated)
KMDA Kamada	$20.20M	$0.38	21.26	13.93	0.68	11.60%	8.37%	5.85%	11/9/2026 (Estimated)
TECX Tectonic Therapeutic	-$74.15M	-$4.57	N/A	N/A	N/A	N/A	-35.26%	-33.59%	11/5/2026 (Estimated)

Latest COYA, KMDA, TECX, and EDIT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/5/2026	Q3 2026	TECX Tectonic Therapeutic	-$1.38	N/A	N/A	N/A	N/A	N/A
8/12/2026	Q2 2026	KMDA Kamada	$0.1125	$0.16	+$0.0475	$0.16	$50.84 million	$54.92 million
8/11/2026	Q2 2026	COYA Coya Therapeutics	-$0.3457	-$0.28	+$0.0657	-$0.28	$0.13 million	$0.24 million
8/6/2026	Q2 2026	TECX Tectonic Therapeutic	-$1.35	-$1.18	+$0.17	-$1.18	N/A	N/A
8/5/2026	Q2 2026	EDIT Editas Medicine	-$0.2705	-$0.15	+$0.1205	-$0.15	$2.85 million	$11.89 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
COYA Coya Therapeutics	N/A	N/A	N/A	N/A	N/A
EDIT Editas Medicine	N/A	N/A	N/A	N/A	N/A
KMDA Kamada	$0.13	1.61%	N/A	34.21%	N/A
TECX Tectonic Therapeutic	N/A	N/A	N/A	N/A	N/A

Latest COYA, KMDA, TECX, and EDIT Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
8/17/2026	KMDA Kamada	annual	$0.17	2.06%	8/27/2026	8/27/2026	9/17/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
COYA Coya Therapeutics	N/A	13.40	13.40
EDIT Editas Medicine	N/A	3.19	3.19
KMDA Kamada	N/A	4.06	2.29
TECX Tectonic Therapeutic	N/A	22.29	22.29

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
COYA Coya Therapeutics	39.75%
EDIT Editas Medicine	71.90%
KMDA Kamada	20.38%
TECX Tectonic Therapeutic	62.63%

Insider Ownership

Company	Insider Ownership
COYA Coya Therapeutics	6.10%
EDIT Editas Medicine	3.10%
KMDA Kamada	36.10%
TECX Tectonic Therapeutic	39.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
COYA Coya Therapeutics	8	23.46 million	22.03 million	Not Optionable
EDIT Editas Medicine	87	153.58 million	148.82 million	Optionable
KMDA Kamada	462	57.51 million	36.75 million	Optionable
TECX Tectonic Therapeutic	60	19.55 million	11.77 million	N/A

COYA, KMDA, TECX, and EDIT Headlines

Recent News About These Companies

Tectonic Therapeutic (NASDAQ:TECX) Stock Rating Raised to Sell at Wall Street Zen

October 10 at 1:06 AM | americanbankingnews.com

Tectonic Therapeutic (NASDAQ:TECX) Upgraded to "Sell" at Wall Street Zen

October 10 at 1:05 AM | marketbeat.com

Tectonic Therapeutic (NASDAQ:TECX) Insider Peter Mcnamara Sells 536 Shares of Stock

October 3, 2026 | americanbankingnews.com

Tectonic Therapeutic (NASDAQ:TECX) Insider Sells 536 Shares of Company Stock

October 2, 2026 | marketbeat.com

Analysts Offer Insights on Healthcare Companies: Tectonic Therapeutic (TECX) and Solid Biosciences (SLDB)

October 1, 2026 | theglobeandmail.com

Tectonic Therapeutic Says TX2100 Phase 1a Trial Met Primary Objectives

September 29, 2026 | finance.yahoo.com

Tectonic Therapeutic Announces Favorable Phase 1 Safety, Tolerability and PK Results for TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia (HHT)

September 29, 2026 | globenewswire.com

Tectonic Therapeutic, Inc. (NASDAQ:TECX) Stock Has Average Price Target of $77.25 According to Analysts

September 26, 2026 | marketbeat.com

Tectonic Therapeutic (NASDAQ:TECX) Stock Rating Lowered by Wall Street Zen

September 19, 2026 | marketbeat.com

Tectonic Therapeutic (NASDAQ:TECX) Stock Price Down 6.1% - Here's What Happened

September 10, 2026 | marketbeat.com

First Light Asset Management LLC Purchases 152,983 Shares of Tectonic Therapeutic, Inc. $TECX

September 10, 2026 | marketbeat.com

Tectonic Therapeutic (TECX) Clears Two Trial Hurdles With Cash To Spare

September 10, 2026 | insidermonkey.com

Tectonic Therapeutic to Participate in the Morgan Stanley Global Healthcare Conference

September 3, 2026 | globenewswire.com

Tectonic Therapeutic: Competitor Data Strengthens The TX45 Bull Case

September 2, 2026 | seekingalpha.com

Stifel Nicolaus Reaffirms Their Buy Rating on Tectonic Therapeutic (TECX)

August 13, 2026 | theglobeandmail.com

Analysts Conflicted on These Healthcare Names: Ginkgo Bioworks Holdings (DNA), InflaRx (IFRX) and Tectonic Therapeutic (TECX)

August 7, 2026 | theglobeandmail.com

Tectonic Therapeutic Announces Second Quarter 2026 Financial Results and Recent Business Highlights

August 6, 2026 | finance.yahoo.com

Tectonic Therapeutic Inc

July 2, 2026 | edition.cnn.com

Why Tectonic Therapeutic, Inc.’s (TECX) Stock Is Up 5.05%

June 30, 2026 | aaii.comA

Tectonic Therapeutic Completes Enrollment in Key TX45 Trial

June 10, 2026 | tipranks.com

Tectonic Therapeutic Completes Enrollment in TX45 APEX Phase 2 Clinical Trial in PH-HFpEF Patients

June 10, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

COYA, KMDA, TECX, and EDIT Company Descriptions

Coya Therapeutics NASDAQ:COYA

$4.95 -0.04 (-0.80%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$5.00 +0.05 (+1.01%)

As of 10/9/2026 07:51 PM Eastern

Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic, which is in Phase 2 clinical trial for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. The company was incorporated in 2020 and is headquartered in Houston, Texas.

Editas Medicine NASDAQ:EDIT

$2.90 +0.06 (+2.11%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$2.89 -0.01 (-0.34%)

As of 10/9/2026 07:54 PM Eastern

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Kamada NASDAQ:KMDA

$8.08 +0.30 (+3.86%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$8.09 +0.01 (+0.12%)

As of 10/9/2026 07:56 PM Eastern

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.

Tectonic Therapeutic NASDAQ:TECX

$23.33 +0.58 (+2.55%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$23.31 -0.02 (-0.09%)

As of 10/9/2026 07:30 PM Eastern

Tectonic Therapeutic, Inc. engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest COYA, KMDA, TECX, and EDIT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest COYA, KMDA, TECX, and EDIT Earnings

Compare Dividends

Latest COYA, KMDA, TECX, and EDIT Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

COYA, KMDA, TECX, and EDIT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

COYA, KMDA, TECX, and EDIT Company Descriptions

Coya Therapeutics NASDAQ:COYA

Editas Medicine NASDAQ:EDIT

Kamada NASDAQ:KMDA

Tectonic Therapeutic NASDAQ:TECX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest COYA, KMDA, TECX, and EDIT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest COYA, KMDA, TECX, and EDIT Earnings

Compare Dividends

Latest COYA, KMDA, TECX, and EDIT Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

COYA, KMDA, TECX, and EDIT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

COYA, KMDA, TECX, and EDIT Company Descriptions

Coya Therapeutics NASDAQ:COYA

Editas Medicine NASDAQ:EDIT

Kamada NASDAQ:KMDA

Tectonic Therapeutic NASDAQ:TECX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools